Zabirnyk, A., Ferrer, M.D., Bogdanova, M., Pérez, M.M., Salcedo, C., Kaljusto, M.L., et al. (2019) SNF472, a Novel Anti-Crystallization Agent, Inhibits Induced Calcification in an in Vitro Model of Human Aortic Valve Calcification. Vascular Pharmacology, 122-123, 106583.
https://doi.org/10.1016/j.vph.2019.106583

has been cited by the following article:

• TITLE: Calcific Uremic Arteriolopathy or Calciphylaxis in a Hemodialysis Patient: Case Study and Review of the Literature

  AUTHORS: Modou Ndongo, Nestor Nankeu, Josephine Nkok, Helene Messet, Fabrice Tiako, Mamadou Mouctar Diallo, Misylias Bouaoud, Attia Houyem, Fatiha Lahouel, Djillali Ziane Berroudja, Tayeb Bensalem, Sid Ali Toufik Benyaghla, Catherine Albert, Sidy Mohamed Seck, El Hadji Fary Ka

  KEYWORDS: Calcific Uremic Arteriolopathy, Calciphylaxis, Hemodialysis

  JOURNAL NAME: Open Journal of Nephrology, Vol.12 No.3, September 23, 2022

  ABSTRACT: Calcific uremic arteriolopathy (CUA) is a rare pathology affecting 5% of dialysis patients but with a poor prognosis. It is characterized by calcification and thrombotic lesions of the microcirculation leading to hyperalgesic ischemic skin lesions. Several risk factors have been identified, mainly warfarin treatment, mineral and bone disorders (MBD), inflammation and malnutrition. In the evocative forms, the diagnosis is made based upon the physical examination finding of classic painful ulcerated lesions that are covered by a black eschar. Skin biopsy, due to the risk of aggravation and delayed healing, is only performed in case of doubt diagnosis. The therapeutic attitude due to the lack of solid randomized studies is based on expert consensus and requires a multidisciplinary approach. We report here the case of a patient with CUA revealed in the form of multiple ulcerative-necrotic skin lesions associated with pressure sores and arterial wounds.